Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / TAK - Takeda's refiling for subcutaneous Entyvio gets FDA review


TAK - Takeda's refiling for subcutaneous Entyvio gets FDA review

2023-04-27 09:44:03 ET

  • The U.S. Food and Drug Administration (FDA) accepted for review Takeda's resubmitted application seeking approval for subcutaneous (SC) administration of Entyvio as a maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) after induction therapy with Entyvio intravenous.
  • Takeda said the refiling was aimed to address FDA feedback in a December 2019 Complete Response Letter (CRL).
  • The Japanese drugmaker expects a decision from the FDA by the end of 2023.

For further details see:

Takeda's refiling for subcutaneous Entyvio gets FDA review
Stock Information

Company Name: Takeda Pharmaceutical Company Limited American Depositary Shares
Stock Symbol: TAK
Market: NYSE
Website: takeda.com

Menu

TAK TAK Quote TAK Short TAK News TAK Articles TAK Message Board
Get TAK Alerts

News, Short Squeeze, Breakout and More Instantly...